YDES
HEALTHCAREYD Bio Ltd
$5.19+0.04 (+0.85%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving YDES Today?
No stock-specific AI insight has been generated for YDES yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.73$25.00
$5.19
Fundamentals
Market Cap$368M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.8%
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding70.8M
YDES News
19 articles- YD Bio Limited Reports Full Year 2025 Financial ResultsYahoo Finance·Apr 30, 2026
- YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United StatesYahoo Finance·Mar 31, 2026
- YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology EcosystemYahoo Finance·Mar 17, 2026
- YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory PlatformYahoo Finance·Feb 25, 2026
- YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell TherapyYahoo Finance·Jan 29, 2026
- YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.Yahoo Finance·Jan 13, 2026
- YDES is A Biotechnology Company on the MoveYahoo Finance·Jan 7, 2026
- YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug DevelopmentYahoo Finance·Jan 6, 2026
- YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial RoadmapYahoo Finance·Jan 5, 2026
- YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations CenterYahoo Finance·Dec 16, 2025
- YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWANYahoo Finance·Dec 9, 2025
- YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early DetectionYahoo Finance·Dec 2, 2025
- YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome TherapeuticsYahoo Finance·Nov 24, 2025
- YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer MonitoringYahoo Finance·Nov 5, 2025
- YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing CapabilitiesYahoo Finance·Oct 10, 2025
- YD Bio Limited Reports Unaudited Half Year 2025 Financial ResultsYahoo Finance·Sep 30, 2025
- Breeze Holdings Acquisition (YDES) Rises 31% Over the Past MonthYahoo Finance·Sep 10, 2025
- Top Midday GainersYahoo Finance·Aug 29, 2025
- YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global MarketYahoo Finance·Aug 29, 2025
All 19 articles loaded
Price Data
Open$5.13
Previous Close$5.15
Day High$5.15
Day Low$5.10
52 Week High$25.00
52 Week Low$4.73
52-Week Range
$4.73$25.00
$5.19
Fundamentals
Market Cap$368M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-2.8%
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding70.8M
About YD Bio Ltd
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.
Listed August 29, 2025
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—